Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29128482 | 0.88 | GPR119 (0.43) | GPR119OPRK1NPY2RPKMSMN1; SMN2 | |
| SCHEMBL29128478 | 0.88 | GPR119 (0.43) | GPR119OPRK1NPY2RPKMSMN1; SMN2 | |
| SCHEMBL4286026 | 0.86 | HPGD (0.49) | SMN1; SMN2 | |
| SCHEMBL4281983 | 0.86 | L3MBTL1 (0.48) | HRH3PKMSMN1; SMN2 | |
| SCHEMBL3494366 | 0.84 | TEAD1 (0.50) | SMN1; SMN2 | |
| SCHEMBL4294542 | 0.84 | KDM4E (0.49) | HRH3 | |
| SCHEMBL4286428 | 0.83 | HCRTR1 (0.47) | SMN1; SMN2 | |
| SCHEMBL4281940 | 0.83 | KCNA5 (0.46) | HRH3 | |
| SCHEMBL4287459 | 0.83 | KMT2A (0.49) | HRH3SMN1; SMN2 | |
| SCHEMBL4295216 | 0.83 | KMT2A (0.49) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | GPR119 310/4885OPRK1 2640/4885NPY2R 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.